Jeffrey Frelick - Bone Biologics CEO President
| BBLG Stock | USD 1.05 0.02 1.94% |
CEO
Mr. Jeffrey Frelick serves as Chief Operating Officer of the Company, since August 17, 2015. He was the COO of Life Science Enterprises, where he brings more than 25 years of medtech experience. He spent the past 15 years on Wall Street as a sellside analyst following the medtech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Jeff worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinsons Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Jeff received a B.S. in Biology from University of Pittsburgh and an M.B.A. from Suffolk Universitys Sawyer Business School. since 2015.
| Age | 58 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 2 Burlington Woods Drive, Burlington, MA, United States, 01803 |
| Phone | 781 552 4452 |
| Web | https://www.bonebiologics.com |
Bone Biologics Management Efficiency
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1903) %, meaning that it created substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -2.51. The Bone Biologics' current Return On Capital Employed is estimated to increase to -3.08. At this time, Bone Biologics' Other Assets are most likely to increase significantly in the upcoming years. The Bone Biologics' current Debt To Assets is estimated to increase to 347.01, while Total Current Assets are projected to decrease to roughly 2.3 M.Similar Executives
| Found 6 records | CEO Age | ||
| Steven Foster | Tenon Medical | 56 | |
| Andrew Simpson | Heart Test Laboratories | 55 | |
| Robert Spignesi | Rapid Micro Biosystems | 55 | |
| Brian Murphy | NanoVibronix | 67 | |
| Eric Olson | SINTX Technologies | 61 | |
| Nestor Jaramillo | Nuwellis | 67 | |
Management Performance
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 |
Bone Biologics Corp Management Team
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda, CoFounder Board | ||
| Deina Walsh, Chief Officer | ||
| Jeffrey Frelick, CEO President |
Bone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bone Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (979.72 K) | ||||
| Shares Outstanding | 2.46 M | ||||
| Shares Owned By Insiders | 5.21 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 70.41 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.68 X | ||||
| EBITDA | 479.57 K |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.